In a letter to California Democratic Senator Dianne Feinstein, FDA’s Acting Associate Commissioner for Legislation Dayle Cristinzio acknowledges the agency’s limited insight into cosmetic formulations and safety information, which makes it a struggle to respond to issues as they arise. Feinstein characterizes the letter as an admission of current system failings and a nod of support for her Personal Care Products Safety Act.
FDA has delineated the scope of its regulatory authority over cosmetics and suggested the need for reform measures in communications to stakeholders, but rarely so directly as in a recent letter to Sen. Dianne Feinstein, D-Calif., sponsor of the proposed Personal Care Products Safety Act.
According to Feinstein and co-sponsor Sen. Susan Collins, R-Maine, FDA was consulted extensively as the PCPSA, S. 1014, was being...
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.
Legislator education is key to checking state bills that overreach, says Ross, executive VP of government affairs at the Personal Care Products Council, discussing the rising tide of US state bills aimed at restricting ingredient use.
FDA reminds companies which registered with agency solely to manufacture OTC sanitizers during COVID-19 public health emergency they will be subject to FY2025 OTC monograph user fees if they don’t delist and deregister as monograph drug manufacturers by 12 a.m. on 31 December.
With monographs@FDA portal down, agency moves to NextGen and extends comment period through 27 September for first OTC monograph change it proposed using its overhauled program other than 32 monographs finalizations required in 2020 legislation authorizing overhaul.
OTC sales edged up at Italy's Recordati in the first half of 2024 as higher demand for GI products and supplements offset a weaker cold & flu season.
P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.
